RESUMEN
Background: Multiplex real-time RT-PCR assays for respiratory pathogens are valuable tools to optimize laboratory workflow and turnaround time. At a time when resurgence of influenza and respiratory syncytial virus (RSV) cases have been widely observed along with continued transmission of SARS-CoV-2, timely identification of all circulating respiratory viruses is crucial. This study evaluates the detection of low viral loads of SARS-CoV-2 by four multiplex molecular assays: Roche cobas 6800/8800 SARS-CoV-2 & Influenza A/B Test, Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV, cobas Liat SARS-CoV-2 & Influenza A/B, and a laboratory-developed test (LDT). Methods: Retrospective upper respiratory tract specimens positive for various respiratory viruses at a range of cycle threshold (Ct) values (18-40) were tested by four multiplex assays. Positive and negative percent agreement (PPA and NPA) with validated RT-PCR assays were calculated. Results: A total of 82 samples were assessed, with discordant results observed in a portion of the samples (10/82, 12.2%) where Ct values were >33. The majority of the discordant results (6/10, 60%) were false negatives. Overall, PPA was 100% (58/58) for cobas 6800, 97.4% (38/39) for GeneXpert, 100% (17/17) for Liat, and 90.5% (57/63) for the LDT. PPA for the LDT increased to 92.1% after manual review of amplification curves. Conclusions: Commercial multiplex respiratory virus assays have good performance for samples with medium to high viral loads (Ct values <33). Laboratories should consider appropriate test result review and confirmation protocols to optimize sensitivity, and may consider reporting samples with additional interpretive comments when low viral loads are detected.
Historique: Les dosages multiplex par RT-PCR en temps réel (amplification en chaîne par polymérase avec transcription inverse en temps réel) des agents pathogènes respiratoires sont des outils précieux pour optimiser le flux de travail et le temps de traitement en laboratoire. Alors qu'on observe une résurgence générale des cas d'influenza et du virus respiratoire syncytial (VRS) et une transmission continue du SRAS-CoV-2, il est crucial de détecter rapidement tous les virus respiratoires en circulation. Dans la présente étude, les chercheurs ont évalué la détection des faibles charges virales du SRAS-CoV-2 à l'aide de quatre dosages moléculaires multiplex : le test cobas 6800/8800 SRAS-CoV-2 et influenza A/B de Roche, le test Xpress SRAS-CoV-2/influenza/VRS de Cepheid Xpert, le test cobas SRAS-CoV-2 et influenza A/B de Liat et un test créé par le laboratoire (TCL). Méthodologie: Les chercheurs ont procédé au dépistage rétrospectif d'échantillons ayant obtenu un résultat positif à divers virus respiratoires à une série de valeurs de cycle seuil (Ct) (1840) à l'aide de quatre dosages multiplex. Ils ont calculé le pourcentage de concordance positif (PCP) et négatif (PCN) avec les dosages par RT-PCR validés. Résultats: Au total, les chercheurs ont évalué 82 échantillons et observé des résultats discordants dans une partie des échantillons (dix sur 82, 12,2 %), pour lesquels les valeurs Ct étaient supérieures à 33. La majorité de ces résultats discordants (six sur dix, 60 %) étaient faussement négatifs. Dans l'ensemble, le PCP atteignait 100 % (58 sur 58) selon le test cobas 6800, 97,4 % (38 sur 39) selon le test GeneXpert, 100 % (17 sur 17) selon le test Liat et 90,5 % (57 sur 63) selon le TCL. Le PCP du TCL est passé à 92,1 % après l'examen manuel des courbes d'amplification. Conclusions: Les dosages multiplex commerciaux des virus respiratoires donnent un bon rendement pour les échantillons contenant une charge virale modérée à élevée (valeurs Ct inférieures à 33). Les laboratoires devraient envisager de procéder à une analyse des résultats du dépistage et à des protocoles de confirmation appropriés pour en optimiser la sensibilité et pourraient également envisager d'ajouter des commentaires interprétatifs aux résultats des échantillons lorsque la charge virale décelée est faible.
RESUMEN
Background and Aim: Patients suspected of Alpha 1-Antitrypsin (A1AT) abnormality based on low serum concentration are routinely confirmed through polymerase chain reaction (PCR) testing of peripheral blood. Genotyping formalin-fixed paraffin-embedded (FFPE) tissue is a novel approach that could aid in detecting variant A1AT. We performed qPCR on FFPE liver explants with Periodic Acid Schiff after Diastase (PASD)- and A1AT-positive globules to confirm and estimate the frequency of A1AT deficiency in transplant cases. Materials and Methods: Eighteen (12.68%) of 142 patients with end-stage liver disease showed PASD/A1AT positive globules. FFPE of the explants was tested through qPCR to detect S and Z alleles. A second age- and sex-matched control group consisting of five liver transplant patients with negative globules was included in the study. Results: qPCR assay was successful with all the samples meeting QC parameters. All patients included in the study elucidated Z allele variants; 2 homozygous (11.1%) and 16 heterozygous (88.9%). The control group demonstrated normal wild-type MM allele. Conclusion: Screening for A1AT deficiency using serum levels is not sufficiently sensitive to detect deficiency, especially in carriers. If A1AT testing was not performed preoperatively and the risk is high based on the PASD/A1AT-positive globules in the explants, then molecular testing of FFPE tissue can be a viable method for confirming the diagnosis.
RESUMEN
Introduction. BK polyomavirus (BKPyV) quantitative testing is an important screening tool post-transplantation, although interpretation can be challenging due to lack of standardization, assay heterogeneity and variability of BKPyV DNA over time (in urine).Methods. Remnant clinical EDTA plasma and urine samples were tested by the cobas BKV test and a validated laboratory-developed test (LDT). Accuracy [positive and negative percent agreement (PPA and NPA), Pearson's correlation, Bland-Altman analysis] and reproducibility were evaluated. To assess BKPyV DNA stability in urine, prospective urine samples were maintained at two different storage temperatures and tested in triplicate over 7 days.Results. Overall PPA was 95.6 % (43/45) and NPA was 94.4 % (170/180). For plasma, Pearson's correlation (0.950) and Bland-Altman analysis (0.113±0.22 log10 IU ml-1) showed high agreement. For neat urine, Pearson's correlation (0.842) and Bland-Altman analysis (0.326±0.80 log10 IU ml-1) showed somewhat higher variability. Reproducibility was high for the cobas BKV versus the LDT. BKPyV DNA levels in neat urine remained relatively stable over 7 days at both storage temperatures, although outlier results were intermittently detected.Conclusion. The cobas BKV test showed high agreement and reproducibility compared to the reference LDT. BKPyV viral load testing in urine has known limitations, but neat urine can be processed by the cobas BKV.
Asunto(s)
Virus BK , Ácidos Nucleicos , Estudios Prospectivos , Reproducibilidad de los Resultados , ADNRESUMEN
BACKGROUND: Molecular syndromic panels can improve rapidity of results and ease clinical laboratory workflow, although caution has been raised for potential false-positive results. Upon implementation of a new panel for infectious diarrhea (BioFire® FilmArray® Gastrointestinal [GI] Panel, bioMérieux) in our clinical laboratory, a higher than expected number of stool samples with norovirus were detected. OBJECTIVES: The goal of this study was to investigate positive percent agreement and the false-positive rate of norovirus detected by the multiplex BioFire GI panel compared to a singleplex commercial assay. STUDY DESIGN: From October 2023 to January 2024, all prospective stool samples with a positive norovirus result by BioFire had melting curves reviewed manually using the BioFire FilmArray Torch System. Stool samples further underwent testing by a supplementary real-time RT-PCR assay (Xpert® Norovirus, Cepheid) for comparative analysis. RESULTS: Of the 50 stool samples with norovirus detected by BioFire, 18 (36 %) tested negative by Xpert (deemed "false-positives"). Furthermore, melting curve analysis revealed nearly all of these samples had atypical melting curve morphologies for the "Noro-1" target on BioFire (16/18, 89 %), which was statistically significant (Odds Ratio 173.2, 95 % CI [22.2, 5326.9], p < 0.0001). Stool samples with multiple pathogens detected by BioFire including norovirus were not more likely to produce false-positive norovirus results (Odds Ratio 1, 95 % CI [0.3, 3.3], p = 1). CONCLUSIONS: Although not described in the manufacturer's Instructions for Use, we propose routine manual review of melting curves for the BioFire GI panel prior to reporting, to mitigate potential false-positive norovirus results.